Glutipyran is a small-molecule glucose transporter inhibitor, inhibits glycolytic activity and cell growth in human pancreatic cancer cells.
Glutipyran inhibited glucose uptake and suppressed the growth of various cancer cells, including A431 cells that express glucose transporter class I (GLUT1) and DLD-1 GLUT1 knockout cells.
Glutipyran exhibited a synergistic antiproliferative effect, when combined with the mitochondrial respiration inhibitor metformin.
Glutipyran markedly decreased most metabolites of the glycolytic pathway and the pentose phosphate pathway.
Glutipyran significantly suppressed tumor growth in a xenograft mouse model of pancreatic cancer.
